Blue cross focalpoint
![Hasten down the wind zevon lyrics](https://loka.nahovitsyn.com/27.jpg)
![blue cross focalpoint blue cross focalpoint](https://galatea.shopinde.com/sites/default/files/styles/medium/public/slideshow/6/2017-07/CROSS-001.jpg)
Senseonics' CGM systems, Eversense ® and Eversense ® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease.
![blue cross focalpoint blue cross focalpoint](https://www.homethreads.com/files/modway/eei-4284-lbu-5-.jpg)
The Eversense CGM System is a prescription device patients should talk to their health care provider to learn more.
![blue cross focalpoint blue cross focalpoint](https://i.etsystatic.com/9875735/r/il/1d0918/1896739236/il_fullxfull.1896739236_dgfj.jpg)
The sensor insertion and removal procedures are performed by a health care provider. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. The Eversense ® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. Patients and healthcare providers interested in learning more can go to About Eversense The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
![blue cross focalpoint blue cross focalpoint](https://cdn.shopify.com/s/files/1/0171/0806/products/CS536-GP51Z2490_1024x1024.jpg)
Eversense users now have the freedom to make treatment decisions based on their Eversense readings. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose that can be removed, recharged and re-attached to the skin without discarding the sensor. The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. Eversense offers patients a new choice in the CGM class that delivers outstanding accuracy and patient experience, and an opportunity to achieve improved health outcomes.” Given this new environment, it is becoming even more vital for patients to have an array of options to better manage their diabetes. “Improved glucose control for patients with diabetes has always been a focal point for health care professionals, but now more than ever we are seeing the impacts of poor glucose control in patients who contract COVID-19. “We are excited to see the continued progress on the expansion of coverage for Eversense as the payer community recognizes the value Eversense provides for patients using insulin to manage their diabetes and the need for more CGM options,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. Independence Blue Cross and AmeriHealth have also opened the door to coverage for Eversense as they serve approximately 4.8 million people in Pennsylvania and surrounding markets. CareFirst Blue Cross and Blue Shield offers health plans and administrative services to approximately 3.3 million individuals and employers in Maryland, the District of Columbia, and Northern Virginia and has expanded coverage for Eversense. These recent coverage decisions add to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.īlue Cross and Blue Shield of Arizona has added coverage for Eversense which expands access to approximately 1.5 million Arizona residents. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that three more Blue Cross Blue Shield plans are now providing coverage for the Eversense ® CGM System, effective immediately. Blue Cross and Blue Shield coverage decisions add nearly 10 million covered lives for Eversense CGM. Senseonics Announces Positive Coverage Decision for Eversense CGM from Several Blue Cross Blue Shield Plans
![Hasten down the wind zevon lyrics](https://loka.nahovitsyn.com/27.jpg)